Shares of iRhythm Technologies Inc. (NASDAQ: IRTC) plummeted nearly 10% in pre-market trading on Wednesday, following the company's third-quarter earnings report that highlighted ongoing regulatory challenges and higher-than-expected losses, despite strong revenue growth.
The medical technology company reported revenue of $147.5 million for the quarter, representing an 18.4% year-over-year increase. However, the adjusted net loss widened to $39.2 million, or $1 per share, missing analyst estimates. The company attributed the larger losses to increased legal and consulting fees related to FDA remediation efforts and a DOJ subpoena.
Perhaps more concerning for investors was the news that iRhythm had voluntarily delayed regulatory submissions for its anticipated ZCT system, pushing the expected filing to the third quarter of 2025. The delay was prompted by the company's desire to address potential FDA questions, following a warning letter in 2023 and recent 483 observations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。